Canon Medical Systems has received clearance from the U.S. Food and Drug Administration (FDA) for additional neurological and cardiac magnetic imaging capabilities to be performed using the Vantage Galan™ 3T XGO Edition magnetic imaging (MR) scanner. The newly approved advanced gradient and imaging software can provide up to 30% signal-to-noise ratio for brain diffusion weighted imaging (DWI), thus producing higher resolution images. Sequences for quantitative analysis facilitate the completion of cardia examinations with fewer breath holds.
Equipped with the all-new Saturn X Gradient and with PURERF technologies, Galan 3T XGO Edition offers the ability to conduct quick, comfortable and high-quality neurological imaging exams, and allows for faster sampling and higher resolution images. MultiBand SPEEDER software technology, which allows for multiple slices to be acquired at the same time, reduces diffusion weighted imaging scan times by up to two times.
The Galan 3T XGO Edition also delivers enhanced cardiac capabilities, including T1 mapping that utilizes MOdified Look-Locker Inversion recovery (MOLLI) sequence and allows providers to acquire a more quantitative characterization of myocardial tissue within a single breath hold. The system’s Phase Sensitive Inversion Recovery (PSIR) in the heart provides improved contrast in late-enhanced imaging and eliminates the need for inversion time (TI) calibration scan, allowing cardiac exams to be completed with fewer breath holds and greater patient comfort.Back To Top
FDA clears new applications for Canon’s Vantage Galan 3T XGO Edition MRI . Appl Radiol.